U.S. markets open in 8 hours 50 minutes

FDA lifts hold on Flexion's lead drug

Dec 1 (Reuters) - The U.S. Food and Drug Administration lifted a clinical hold on Flexion Therapeutics Inc's lead experimental drug to relieve osteoarthritis-related pain, allowing the company to resume mid-stage trials.

The agency had halted trials of the injectable drug, FX006, in September after one patient's knee was infected.

Flexion said it also plans to initiate a late-stage trial testing the drug early next year.

(Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)